In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I

Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis

“…These studies suggest that this pathway might be a fruitful line of investigation for future studies. The recent publication by Zhao et al ( 69 ) showing that an apoA-I mimetic peptide structurally different from the 4F and 6F peptides was effective after oral administration despite the absence of detectable plasma levels strongly suggests that the site of action for multiple apoA-I mimetic peptides may be in the gut ( 69,70 ). The results reported here suggest that studying the role of apoA-I mimetic peptides in LysoPC metabolism in the small intestine may be a fruitful line of research.…”

Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review

“…Under in vitro conditions, nanoparticles incorporated into HDL converted the native lipoprotein into a lipid-poor HDL particle and were effective mediators of macrophage cholesterol effl ux ( 66 ). A trimeric structure was subsequently generated by linking three copies of the peptide to an organic scaffold, followed by incorporation into nanoparticles ( 89 ). Administration of these HDL nanoparticles (either orally or by IP administration) increased HDL-C, while reducing VLDL-C/LDL-C and aortic lesion area in LDLR Ϫ / Ϫ mice ( 89 ).…”

“…A trimeric structure was subsequently generated by linking three copies of the peptide to an organic scaffold, followed by incorporation into nanoparticles ( 89 ). Administration of these HDL nanoparticles (either orally or by IP administration) increased HDL-C, while reducing VLDL-C/LDL-C and aortic lesion area in LDLR Ϫ / Ϫ mice ( 89 ).…”

Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut?

“…This issue of the Journal of Lipid Research contains an intriguing paper from the Scripps Research Institute by Zhao and colleagues ( 1 ) investigating the in vivo antiatherosclerotic properties of HDL-like nanoparticles containing α -helical amphipathic peptides. The group uses 23-amino acid peptides representing a modifi ed tenth helix of human apoA-I (amino acid residues 221-241, modifi ed sequence = CGVLESFKASFLSALEEWTKKLQ).…”